All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
A Single-arm, Open-label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715, an Anti-BMCA Allogeneic CAR T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma
SWOG-S1803-CTN-1706: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide OR Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with MM Using MRD To Direct Therapy Duration (DRAMMATIC STUDY)
Phase 1 Study of Nivolumab in Combination with Tocilizumab for Treatment of Patients with Relapsed Hematological Malignancy Post-Allogeneic Transplant
Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients
Alliance-A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with CLL
Phase 2 Trial of Intensive Chemo-immunotherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation
This is a phase I trial. The purpose of the study is to observe the safety, efficacy (good or bad) and determine the maximum dose of Lintuzumab-Ac225 that can be given to patients with multiple myeloma like you without causing bad effects.